Yahoo Finance Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shareholders over the last year, as the share price declined 47%. That falls noticeably short of the market return of around 2.9%. Longer term investors have fared much better, since the share price is up 11% in three years. The falls have accelerated recently, with the share price down 18% in the last three months.
View our latest analysis for Momenta Pharmaceuticals
Given that Momenta Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Momenta Pharmaceuticals's revenue didn't grow at all in the last year. In fact, it fell 36%. That looks pretty grim, at a glance. The stock price has languished lately, falling 47% in a year. That seems pretty reasonable given the lack of both profits and revenue growth. We think most holders must believe revenue growth will improve, or else costs will decline.
You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).
Take a more thorough look at Momenta Pharmaceuticals's financial health with this free report on its balance sheet.
A Different Perspective
While the broader market gained around 2.9% in the last year, Momenta Pharmaceuticals shareholders lost 47%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.3% per year over five years. We realise that Buffett has said investors should 'buy when there is blood on the streets', but we caution that investors should first be sure they are buying a high quality businesses. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.
Of course Momenta Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
